Picotamide in migraine aura prevention: a pilot study - PubMed

Affiliations

• PMID: 15549555
• DOI: 10.1007/s10072-004-0304-6

Clinical Trial

Picotamide in migraine aura prevention: a pilot study

G Allais et al. Neurol Sci. 2004 Oct.

Abstract

In an open, preliminary trial we evaluated the use of picotamide, an antiplatelet drug, in the prophylactic treatment of migraine aura (MA). Twenty-two women suffering from migraine with typical aura or MA without headache, diagnosed according to International Headache Society criteria, entered a nine-month study. They underwent a three-month run-in period free of prophylactic drugs, followed by a six-month treatment period (subdivided in two trimesters, TI and TII) with 300 mg of picotamide administered twice daily. A detailed diary reporting neurological symptoms, duration and frequency of MA was compiled by patients along the trial time. The number of MA significantly decreased during treatment (from 6.85+/-3.82 in the run-in trimester to 2.85+/-2.72 during TI and to 2.55+/-2.89 during TII). Also, MA duration was decreased significantly, being 36.75+/-20.28 min during run-in, 20.00+/-16.94 during TI and 17.75+/-16.26 during TII. In 25% of patients MA totally disappeared. The number and the features of aura neurological symptoms were also positively modified by the use of picotamide. No serious adverse event was provoked by picotamide administration. Picotamide is effective in reducing MA frequency, duration and symptomatology. The effect is clearly evident in the first trimester of treatment and is maintained with no further modifications during the second trimester.

Similar articles

• Efficacy of Ginkgolide B in the prophylaxis of migraine with aura.

  D'Andrea G, Bussone G, Allais G, Aguggia M, D'Onofrio F, Maggio M, Moschiano F, Saracco MG, Terzi MG, Petretta V, Benedetto C. D'Andrea G, et al. Neurol Sci. 2009 May;30 Suppl 1:S121-4. doi: 10.1007/s10072-009-0074-2. Neurol Sci. 2009. PMID: 19415441 Clinical Trial.

• Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study.

  Brighina F, Palermo A, Aloisio A, Francolini M, Giglia G, Fierro B. Brighina F, et al. Clin Neuropharmacol. 2006 Nov-Dec;29(6):338-42. doi: 10.1097/01.WNF.0000236766.08409.03. Clin Neuropharmacol. 2006. PMID: 17095897

• Treatment of aura: solving the puzzle.

  D'Andrea G, Nordera GP, Allais G. D'Andrea G, et al. Neurol Sci. 2006 May;27 Suppl 2:S96-9. doi: 10.1007/s10072-006-0579-x. Neurol Sci. 2006. PMID: 16688638 Clinical Trial.

• Migraine with aura from pathophysiology to treatment: therapeutic strategies.

  D'Andrea G, Allais G, Grazzi L, Fumagalli L. D'Andrea G, et al. Neurol Sci. 2005 May;26 Suppl 2:s104-7. doi: 10.1007/s10072-005-0420-y. Neurol Sci. 2005. PMID: 15926005 Review.

• A review of picotamide in the reduction of cardiovascular events in diabetic patients.

  Celestini A, Violi F. Celestini A, et al. Vasc Health Risk Manag. 2007;3(1):93-8. Vasc Health Risk Manag. 2007. PMID: 17583179 Free PMC article. Review.

Cited by

• Visual disturbances and migraine.

  Maxner CE, Moeller JJ. Maxner CE, et al. Curr Neurol Neurosci Rep. 2005 Sep;5(5):376-81. doi: 10.1007/s11910-005-0061-9. Curr Neurol Neurosci Rep. 2005. PMID: 16131420 Review.

• Migraine with aura: conventional and non-conventional treatments.

  D'Andrea G, Colavito D, Dalle Carbonare M, Leon A. D'Andrea G, et al. Neurol Sci. 2011 May;32 Suppl 1:S121-9. doi: 10.1007/s10072-011-0529-0. Neurol Sci. 2011. PMID: 21533727 Review.

• Visual Snow: a Potential Cortical Hyperexcitability Syndrome.

  Bou Ghannam A, Pelak VS. Bou Ghannam A, et al. Curr Treat Options Neurol. 2017 Mar;19(3):9. doi: 10.1007/s11940-017-0448-3. Curr Treat Options Neurol. 2017. PMID: 28349350 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal